-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $64

Benzinga·07/09/2026 10:22:26
Listen to the news
HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $56 to $64.